logo
Being my mom's medical proxy was heartbreaking, but I'd do it all over again

Being my mom's medical proxy was heartbreaking, but I'd do it all over again

CBCa day ago
This First Person article is the experience of Lynn Paulin, who was born and raised in P.E.I. For more information about CBC's First Person stories, please see the FAQ.
On Aug. 22, 2024, I received a text message from my mom. She had decided to go to the emergency room. The back pain she had been dealing with for the past month had become unbearable.
I offered to make the 40-minute drive to the hospital to sit with her. She told me not to make the trip over what she suspected was nothing more than a pulled muscle.
Not wanting to impose, I respected her wishes and stayed home.
I wish I hadn't.
Mom walked into the hospital that night thinking it was a minor injury and walked out the next morning with a diagnosis of Stage 4 metastatic lung cancer that had spread to her spine and crushed one of her vertebrae.
For an entire month, she had been walking around with a broken back.
We barely had time for this news to sink in before phones started ringing from doctors' offices and hospitals informing us of next steps.
Attending medical appointments with Mom was not a new occurrence.
I had been accompanying her regularly since she was diagnosed with Idiopathic Pulmonary Fibrosis (IPF) 18 months earlier.
IPF is defined by the Canadian Lung Association as a chronic lung disease that causes irreversible scarring or "fibrosis" of the lung tissue. As the scarring worsens, the lungs stiffen up and breathing becomes more difficult.
Prior to her diagnosis, I had never heard of IPF. I spent a lot of time researching the disease, hoping to gain a better understanding of what we were up against. Of all the things I learned, the most intriguing one came directly from Mom herself. Thirty-one years prior, in December 1993, her mom passed from the same disease.
The average life expectancy for someone with IPF is three to five years from diagnosis in the absence of a lung transplant.
We knew where things were heading for my mom. The cancer just expedited the inevitable.
Early September saw us spending more time inside the hospital. The frequency of appointments increased while Mom's stamina and vitality waned. Multiple times a week, I found myself standing with my arms crossed, peppering doctors with questions, mimicking a level of concern I learned from years of watching her do the same for her own children.
My brother and I were Mom's whole world. This was reflected in the anxious body language she tried her best to hide whenever something ailed us.
She always kept her arms crossed while talking to doctors. It wasn't until I was older that I realized why she did it. She was hiding her shaking hands. Even in her most vulnerable moments, she was being strong for us.
Most of us expect to care for our parents at some point. I just didn't expect to do it in my 30s. Not for Mom anyway.
My dad has long suffered from a myriad of pre-existing and self-inflicted health conditions. There was always an unspoken awareness that something bad could happen sooner rather than later. It never crossed my mind to think Mom would be sooner.
By Sept. 22, 2024, almost two weeks had passed since mom had eaten or drunk more than a couple of sips of a protein shake. She could no longer walk and was asleep more than she was awake.
I told her it was time to go to the hospital. She was too weak to protest. I assisted her to the car and, for the first time, really felt the weight of how frail she had become.
While waiting to be admitted, Mom said something that instantly made me break into a cold sweat.
"There are birds flying around the room. Can you see them?" she asked.
I dug through the giant folder of pamphlets and info sheets given to us by her doctor until I found what I was looking for: a medical directive.
A medical directive allows the patient to assign someone else to make decisions regarding their care.
While we waited for the doctor, we spoke about her wishes. We agreed that Dad's love for her, combined with his predisposition for rash decision-making, may not be the best fit in this situation. We didn't want to add any additional strain on my younger brother, whose first child was due in early December. So, the honour naturally fell to me.
I signed the form, knowing it would eventually be relevant, but thinking I had time to prepare.
I didn't.
On Sept. 25, I received a call from the hospital informing me that my mom was declining and I needed to get there as soon as possible. The same 40-minute drive I opted not to make barely a month prior became the most critical trip of my life. On the way to the hospital, I stopped to pick up my mom's niece for extra support.
My brother, his heavily pregnant partner, and my dad arrived soon after.
Mom was in a small isolation room transitioning between moments of deep sleep and partial lucidity.
She knew who we were and why we were there, but not much else.
WATCH | Over 1 million young Canadian caregivers need help, experts say:
Over 1 million young Canadian caregivers need help, experts say
18 days ago
Duration 2:04
Canada has more than one million young caregivers between the ages of 15 and 30 who are looking after loved ones with long-term health problems, and health-care workers say that without more support, they risk harm to their well-being.
I learned that due to Mom's delirium, all decisions about her care would be deferred to me.
The doctor asked what kind of life-saving measures should be taken into consideration if her heart stopped or she could no longer breathe independently.
The child in me wanted to scream, "That's my mom, do whatever you have to do to save her!" But it's because I was her child that I knew that's not what she would want.
I was faced with the most important decision of my life, and the only person whose advice I wanted couldn't help.
Ultimately, I decided the treatment should be to keep her comfortable. In the early morning hours of the next day, with just the two of us in the room, the woman who watched me take my first breath took her last. She was 62.
She was light, love and selflessness personified. She spent decades going above and beyond for those around her and never asking anything in return.
When I was 16, hundreds of dollars and all her spare time for weeks were spent on sewing me a dress from scratch, only for me to break up with my boyfriend two weeks before prom. Instead of being furious when I told her I would no longer need the dress she had worked so hard on, she hugged me and asked if I was OK. That's just who she was.
That's why I didn't hesitate to step in when she was the one in need of care. Without my knowing, she had been preparing me for this my whole life. Serving was the blueprint for how she showed unconditional love and understanding. Her influence built the foundation on which I live my life.
I wanted to make sure she spent her final weeks enshrouded in the same warmth she so freely gave to others.
Though the final chapter of her life's story has ended, her legacy endures as long as I carry the best parts of her within me.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Canadian curler, 20, paralyzed by rare condition: 'She can't move her legs, sit up, or care for herself'
Canadian curler, 20, paralyzed by rare condition: 'She can't move her legs, sit up, or care for herself'

National Post

time43 minutes ago

  • National Post

Canadian curler, 20, paralyzed by rare condition: 'She can't move her legs, sit up, or care for herself'

A 20-year-old woman and curler from B.C. has been left paralyzed by a rare neurological condition called transverse myelitis. Article content The story of Brook Aleksic has been shared on fundraising website GoFundMe. Aleksic's former curling coach, Diane Dezura, an Olympic bronze medalist in the sport, organized the fundraiser. As of Monday, it was around $6,000 shy of its $100,000 goal. Article content Article content 'Her onset was rapid and severe,' according to the fundraising site. 'She can't move her legs, sit up, or care for herself. The damage to her spinal cord is extensive. While there is hope for some recovery, her path will be long, uncertain and expensive.' Article content Article content Canadian filmmaker Josephine Anderson, who directed Curl Power, filmed Aleksic and her curling teammates 'for much of their teenagehood, as they pursued their dream of becoming national champions,' she told National Post in an email over the weekend. Anderson said audience members connected with Aleksic. Article content 'Brook always leans towards gratitude and optimism, even when facing difficult moments in her life,' said Anderson. 'When we filmed, Brook was bravely open about struggling with body image and self confidence. We had many, many audience members tell us that Brook was especially inspirational to them.' Article content Anderson urged anyone who could help Aleksic and her family 'during this life altering time' to 'please come forward' to offer support. Article content Article content 'Becoming paralyzed in a matter of hours is surely the biggest and scariest challenge she's had to face,' Anderson told National Post. 'But somehow Brook is still finding a way to look on the bright side.' Article content It's caused by inflammation of the spinal cord, which can damage myelin, the insulating material that covers your nerves, explains a webpage about the condition by Johns Hopkins University School of Medicine. There is no cure, but there are treatments that include high doses of steroids or plasma exchange therapy. Article content A third of those with transverse myelitis can have a full or near-full recovery, per Johns Hopkins. Another third can have 'fair recovery' while the final third could 'recover poorly and have major physical disabilities.' Recovery can take up to two years.

N.S. construction workers facing high stress levels: survey
N.S. construction workers facing high stress levels: survey

CTV News

timean hour ago

  • CTV News

N.S. construction workers facing high stress levels: survey

Construction workers in Nova Scotia are facing high stress levels leading to mental health challenges, according to a new survey. Construction workers in Nova Scotia are facing high stress levels leading to mental health challenges, according to a new survey. Construction workers in Nova Scotia are dealing with very high stress levels, according to a newly released survey. The survey, which was done by Construction Safety Nova Scotia (CSNS) in partnership with research firm WorkInsights, was conducted in spring 2024. More than 1,000 construction workers from across the province took part. Highlights from the survey include: more than 36 per cent of the workforce experience high or very high stress levels high-stress environments lead to up to 60 per cent more workplace incidents 40 per cent of the workforce is currently considering leaving due to stress The CEO of CSNS says the report confirms what the association has been hearing anecdotally. 'While studies from across Canada and the United States have highlighted mental health challenges in construction, this is the first time we have data specific to Nova Scotia. Now, we can clearly see how our workers are doing and, more importantly, how to help them. This report provides a concrete roadmap for change,' said MJ MacDonald. The survey also found 33 per cent of workplace stress is directly linked to manager interactions and 37 per cent of employees are dissatisfied with their relationship with their manager. Half of all workers surveyed also said they don't feel comfortable discussing mental health with colleagues. Despite this, some positive responses were given. More than 81 per cent of workers said they find genuine purpose in their work, 85 per cent said they clearly understand job expectations, and 74 per cent said feel they are part of a cohesive team. In addition to the findings, the report makes the following recommendations: train and support managers, who are the most influential factor in worker mental health expand access to therapy, especially through online platforms provide managers with the time and resources they need to lead psychologically safe teams CSNS says it will expand its mental health programming with new training programs and resources launching later this year. The Creating Mentally Healthy Workplaces report is available now online. For more Nova Scotia news, visit our dedicated provincial page

Sickle Cell Disease Drugs Market 2034: Clinical Trials, Prevalence, EMA, PDMA, FDA Approvals, Medication, Statistics, NICE Approval.Revenue and Companies by DelveInsight
Sickle Cell Disease Drugs Market 2034: Clinical Trials, Prevalence, EMA, PDMA, FDA Approvals, Medication, Statistics, NICE Approval.Revenue and Companies by DelveInsight

Globe and Mail

time4 hours ago

  • Globe and Mail

Sickle Cell Disease Drugs Market 2034: Clinical Trials, Prevalence, EMA, PDMA, FDA Approvals, Medication, Statistics, NICE Approval.Revenue and Companies by DelveInsight

Sickle Cell Disease companies working in the treatment market are Cellectis, Sana Biotechnology, Global Blood Therapeutics, Inc., CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio, ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others. Sickle Cell Disease Market Summary In 2023, the Sickle Cell Disease (SCD) market across the 6MM was valued at approximately USD 650 million, with the United States dominating at ~USD 603 million (92% share), followed by France and the UK. SCD is a hereditary blood disorder caused by mutations in the HBB gene, resulting in abnormal hemoglobin (HbS) that distorts red blood cells into a sickle shape. These rigid cells obstruct microvasculature, triggering vaso-occlusive crises, anemia, acute chest syndrome, stroke, organ damage, and heightened infection risk, severely impacting patient quality of life and survival. Historically, management relied on NSAIDs, transfusions, chelators, and supportive care, with hydroxyurea (DROXIA) being the primary disease-modifying agent for decades. Recent approvals of ENDARI (L-glutamine), ADAKVEO (crizanlizumab), and OXBRYTA (voxelotor) have expanded options, though challenges in adherence and reimbursement persist. New approvals like CASGEVY (exa-cel) and LYFGENIA (lovo-cel) are expected to drive market growth, alongside pipeline candidates such as EDIT-301, Mitapivat, Inclacumab, and Osivelotor. Despite advances, delays in diagnosis, economic burden, and complications continue to constrain outcomes. Multidisciplinary care, genetic counseling, early intervention, and patient education are critical, while gene therapy and gene editing hold promise for transformative treatment, aiming to mitigate SCD's substantial clinical and economic impact in the coming decade. (Albany, USA) DelveInsight's ' Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2034 ' report delivers an in-depth understanding of Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Sickle Cell Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Sickle Cell Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Sickle Cell Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Sickle Cell Disease market. Some facts of the Sickle Cell Disease Market Report are: According to DelveInsight, Sickle Cell Disease market size is expected to grow at a decent CAGR by 2034. Leading Sickle Cell Disease companies working in the market are Cellectis, Sana Biotechnology, Global Blood Therapeutics, Inc., CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio, ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others. Key Sickle Cell Disease Therapies expected to launch in the market are BPX-501 T cells, Canakinumab, EPI01, CTX001, ADAKVEO, DROXIA, ENDARI, OXBRYTA, and many others. In May 2025, Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicines via base editing, announced it will share new findings from its BEACON Phase 1/2 clinical trial of BEAM-101 at the upcoming European Hematology Association 2025 Congress (EHA2025), scheduled for June 12–15, 2025, in Milan, Italy. BEAM-101 is an investigational ex vivo genetically modified cell therapy being developed to treat sickle cell disease (SCD), specifically in patients experiencing severe vaso-occlusive crises (VOCs). In November 2024, BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial-stage biopharmaceutical company focused on oncology and rare diseases, announced that an abstract featuring initial results from a Phase 1 trial of motixafortide—both as a monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization in gene therapies for sickle cell disease (SCD)—has been accepted for oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 7-10, 2024, in San Diego, California. Conducted in collaboration with Washington University School of Medicine in St. Louis, this proof-of-concept study aims to explore alternative HSC mobilization approaches to enhance the treatment experience for SCD patients undergoing gene therapy. In May 2024, Afimmune announced results of an Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell Disease In April 2024, Pfizer announced results of an Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial In April 2024, Novo Nordisk A/S (Forma Therapeutics, Inc.) announced results of an adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS). In July 2023, Novartis announced results of an Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study. Sickle Cell Disease Overview Sickle cell disease (SCD) is a hereditary blood disorder characterized by the production of abnormal hemoglobin, known as hemoglobin S. This defect causes red blood cells to assume a rigid, sickle-like shape, which impedes their ability to flow smoothly through blood vessels. Consequently, these misshapen cells can obstruct blood flow, leading to severe pain, organ damage, and an increased risk of infection. Sickle cell disease is most prevalent among individuals of African, Mediterranean, Middle Eastern, and Indian ancestry. Symptoms typically appear in early childhood and include episodes of pain (called sickle cell crises), chronic anemia, fatigue, swelling in the hands and feet, and delayed growth. Complications can be severe, including stroke, acute chest syndrome, and organ failure. Management of Sickle cell disease involves both preventive and therapeutic strategies. Preventive measures include regular vaccinations, antibiotics to prevent infections, and hydroxyurea, a medication that reduces the frequency of pain crises and the need for blood transfusions. Pain management, blood transfusions, and bone marrow transplants are critical therapeutic options for managing acute and chronic complications. Recent advancements in gene therapy and CRISPR technology hold promise for more effective treatments and potential cures for Sickle cell disease. Ongoing research and clinical trials aim to improve the quality of life for patients and reduce the burden of this debilitating disease. Do you know what will be the Sickle Cell Disease market share in 7MM by 2034 @ Sickle Cell Disease Treatment Market Sickle Cell Disease Market The Sickle Cell Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Sickle Cell Disease market trends by analyzing the impact of current Sickle Cell Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology. This segment gives a thorough detail of the Sickle Cell Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Sickle Cell Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Sickle Cell Disease market in 7MM is expected to witness a major change in the study period 2020-2034. Sickle Cell Disease Epidemiology The Sickle Cell Disease epidemiology section provides insights into the historical and current Sickle Cell Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Sickle Cell Disease market report also provides the diagnosed patient pool, trends, and assumptions. Interested to know how the emerging diagnostic approaches will be contributing in increased Sickle Cell Disease diagnosed prevalence pool? Download report @ Sickle Cell Disease Market Dynamics and Trends Sickle Cell Disease Drugs Uptake This section focuses on the uptake rate of the potential Sickle Cell Disease drugs recently launched in the Sickle Cell Disease market or expected to be launched in 2020-2034. The analysis covers the Sickle Cell Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Sickle Cell Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Sickle Cell Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Sickle Cell Disease Pipeline Development Activities The Sickle Cell Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Sickle Cell Disease key players involved in developing targeted therapeutics. Download report to know which TOP 3 therapies will be capturing the largest Sickle Cell Disease market share by 2034? Click here @ Sickle Cell Disease Companies and Medication Sickle Cell Disease Therapeutics Assessment Major key companies are working proactively in the Sickle Cell Disease Therapeutics market to develop novel therapies which will drive the Sickle Cell Disease treatment markets in the upcoming years are Cellectis, Sana Biotechnology, Global Blood Therapeutics, Inc., CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio, ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others. Do you know how market launches of New drugs will be impacting the Sickle Cell Disease market CAGR? Download sample report @ Sickle Cell Disease Therapies and Clinical Trials Sickle Cell Disease Report Key Insights 1. Sickle Cell Disease Patient Population 2. Sickle Cell Disease Market Size and Trends 3. Key Cross Competition in the Sickle Cell Disease Market 4. Sickle Cell Disease Market Dynamics (Key Drivers and Barriers) 5. Sickle Cell Disease Market Opportunities 6. Sickle Cell Disease Therapeutic Approaches 7. Sickle Cell Disease Pipeline Analysis 8. Sickle Cell Disease Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Sickle Cell Disease Market Table of Contents 1. Key Insights 2. Executive Summary 3. Sickle Cell Disease Competitive Intelligence Analysis 4. Sickle Cell Disease Market Overview at a Glance 5. Sickle Cell Disease Disease Background and Overview 6. Sickle Cell Disease Patient Journey 7. Sickle Cell Disease Epidemiology and Patient Population 8. Sickle Cell Disease Treatment Algorithm, Current Treatment, and Medical Practices 9. Sickle Cell Disease Unmet Needs 10. Key Endpoints of Sickle Cell Disease Treatment 11. Sickle Cell Disease Marketed Products 12. Sickle Cell Disease Emerging Therapies 13. Sickle Cell Disease Seven Major Market Analysis 14. Attribute Analysis 15. Sickle Cell Disease Market Outlook (7 major markets) 16. Sickle Cell Disease Access and Reimbursement Overview 17. KOL Views on the Sickle Cell Disease Market 18. Sickle Cell Disease Market Drivers 19. Sickle Cell Disease Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store